Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
2.930
-0.070 (-2.33%)
Jun 23, 2025, 4:00 PM - Market closed
Company Description
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
The company’s lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage.
It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN).
The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024.
Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Grace Therapeutics, Inc.
| Country | United States |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Prashant Kohli |
Contact Details
Address: 103 Carnegie Center, Suite 300 Princeton, New Jersey 08540 United States | |
| Phone | 609-322-1602 |
| Website | gracetx.com |
Stock Details
| Ticker Symbol | GRCE |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001444192 |
| ISIN Number | US00439U1043 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Prashant Kohli | Chief Executive Officer and Director |
| Amresh Kumar Ph.D. | Vice President of Program Management |
| Carrie D'Andrea | Vice President of Clinical Operations |
| Robert J. DelAversano CPA | Vice President of Finance and Principal Financial and Accounting Officer |
| Dr. R. Loch MacDonald M.D., Ph.D. | Member of Scientific Advisory Board and Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 23, 2025 | 8-K | Current Report |
| Jun 23, 2025 | 10-K | Annual Report |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 15, 2025 | SCHEDULE 13G | Filing |
| May 8, 2025 | SCHEDULE 13G/A | Filing |
| Apr 9, 2025 | 8-K | Current Report |
| Mar 13, 2025 | EFFECT | Notice of Effectiveness |
| Mar 11, 2025 | UPLOAD | Filing |
| Mar 10, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 3, 2025 | 8-K | Current Report |